Forrest Dolly
Pulmonary Disease · Tallahassee, FLNPI 1508898222
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,269 and has fallen 98.1% since, to $24 in 2023. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 149 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$586
- Jazz Pharmaceuticals Inc.$251
- Insmed, Inc.$225
- GSK$177
- Electromed, Inc.$144
- United Therapeutics Corporation$141
- plus $942 from 18 others
What the payments were for
- Food & beverage$2,42898%
- Education$382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 30 | $586 |
| Jazz Pharmaceuticals Inc. | 13 | $251 |
| Insmed, Inc. | 9 | $225 |
| GSK | 15 | $177 |
| Electromed, Inc. | 12 | $144 |
| United Therapeutics Corporation | 10 | $141 |
| Mylan Specialty L.p. | 8 | $137 |
| Regeneron Healthcare Solutions, Inc. | 6 | $110 |
| Grifols USA, LLC | 8 | $99 |
| AstraZeneca(2 entities) | 7 | $92 |
| Genentech USA, Inc. | 3 | $77 |
| Sanofi | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 3 | $59 |
| Novartis | 3 | $41 |
| Pfizer | 3 | $38 |
| Merck | 3 | $38 |
| Harmony Biosciences LLC | 3 | $37 |
| Resmed Corp | 1 | $19 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
| Inogen, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$133
How this compares
$2,466 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tallahassee
- Carlos CampoTallahassee$87K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.